Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that ...
Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...
Gilead (GILD) stock stock is in focus as the company extends the expiration date for its tender offer to acquire Arcellx ...
On April 13, Citi analyst Geoff Meacham lifted the firm’s price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $165 ...
For Johanna Mercier, Gilead Sciences’ chief commercial and corporate affairs officer, leadership starts with a clear ...
Gilead Sciences (GILD) stock is in focus as the company warns of a $107M Q1 earnings headwind from R&D deal charges as M&A ...
Despite a new supply commitment from Gilead Sciences, Doctors Without Borders/Médecins Sans Frontières (MSF) is poking holes ...
Gilead Sciences just hit a big milestone in Foster City. Crews have set the final steel beam on the company’s new Technical ...
By Sriparna Roy April 7 (Reuters) - Gilead said on Tuesday it would acquire Germany-based Tubulis GmbH for up to $5 billion, ...
Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results